Innovation in bone healing and tissue repair
08 Mar 16
Kuros Biosciences Ltd. appoints Chief Medical Officer

Schlieren (Zurich), Switzerland, March 8, 2016

Kuros Biosciences Ltd. appoints Chief Medical Officer

Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has considerable experience in early and late stage clinical development, product registration and medical affairs. Dr. Jamieson received her medical degree at Edinburgh University and obtained a postgraduate fellowship in anesthesia from the Royal College of Surgeons in London. In addition, she has a diploma from the Faculty of Pharmaceutical Medicine where she has also been an appraiser for revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical Officer and is therefore very familiar with Kuros’ products.

 

Didier Cowling, CEO of Kuros, said: “We are delighted to have Virginia join us again. Her wealth of experience, both in the surgical field and pharmaceutical and medical industry, coupled with her deep knowledge of Kuros’ products, makes this a key appointment for us.”



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
08 Mar 16
Kuros Biosciences Ltd. appoints Chief Medical Officer

Schlieren (Zurich), Switzerland, March 8, 2016

Kuros Biosciences Ltd. appoints Chief Medical Officer

Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has considerable experience in early and late stage clinical development, product registration and medical affairs. Dr. Jamieson received her medical degree at Edinburgh University and obtained a postgraduate fellowship in anesthesia from the Royal College of Surgeons in London. In addition, she has a diploma from the Faculty of Pharmaceutical Medicine where she has also been an appraiser for revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical Officer and is therefore very familiar with Kuros’ products.

 

Didier Cowling, CEO of Kuros, said: “We are delighted to have Virginia join us again. Her wealth of experience, both in the surgical field and pharmaceutical and medical industry, coupled with her deep knowledge of Kuros’ products, makes this a key appointment for us.”